1例晚期非小细胞肺癌并发重度贫血的药学监护

中国药物警戒 ›› 2016, Vol. 13 ›› Issue (12): 757-760.

• 安全性评价与合理用药 • 上一篇下一篇

1例晚期非小细胞肺癌并发重度贫血的药学监护

周殿友¹, 习加喜², 龚倩^{3*, *}

1 晋煤集团总医院药学部,山西晋城048006;
2 广西壮族自治区人民医院药学部,广西南宁 530000;
3 湖南省肿瘤医院药学部,湖南长沙 410000

收稿日期:2017-01-13 修回日期:2017-01-13 出版日期:2016-12-20 发布日期:2017-01-13
通讯作者: 龚倩,女,硕士,副主任药师,临床药学。E-mail：13973185451@163.com。
作者简介:周殿友,女,硕士,药师,临床药学。

Pharmaceutical Care for One Advanced Non-small Cell Lung Cancer Complicated with Severe Anemia

ZHOU Dian-you¹, XI Jia-xi², GONG Qian^{3, *}

1 Department of Pharmacy, Jincheng General Hospital, Shanxi Jincheng 048006, China;
2 Department of Pharmacy, People's Hospital of Guangxi Zhuang Autonomous Region, Guangxi Nanning 530000, China;
3 Department of Pharmacy, Hunan Cancer Hospital, Hunan Changsha 410000, China

Received:2017-01-13 Revised:2017-01-13 Online:2016-12-20 Published:2017-01-13

摘要/Abstract

摘要： 目的探讨临床药师参与抗肿瘤药物治疗的方法和思路。方法通过对1例晚期非小细胞肺癌化疗导致重度贫血的病例分析,分析发生贫血原因,介绍药师协助医师完善相关治疗方法、注意不良反应、指导用药等体会,通过查阅文献考虑患者出现疾病迅速进展与重组人促红素使用有关,并向临床医师提供有关信息资料。结果临床药师以专业特长参与抗肿瘤药物治疗,使患者贫血情况得到了缓解,得到了医护人员的高度认可,促进了合理用药。结论临床实践过程中临床药师应将药物的效益和风险充分告知医生和患者,为临床医师提供良好的用药信息,保证患者用药的安全、有效、合理。

关键词: 临床药师, 贫血, 重组人促红素

Abstract: Objective To explore clinical pharmacists participating in the anti-tumor drug treatment methods and thoughts. Methods Through a case of advanced non-small cell lung cancer chemotherapy leading to severe anemia, the reasons of anaemia were analyzed, and the pharmacist experiences of helping physicians improve relevant treatment methods, paying attention to drug adverse reactions and guiding medication were introduced. It was considered that the rapidly progressing of disease was related to recombinant human erythropoietin by searching literatures, and relevant information was provided to the clinician. Results Clinical pharmacists participated in antitumor drug therapy with professional skills so that anemia of the patient relieved. It was acknowledged by the healthcare professionals, and the rational drug use was promoted. Conclusion In the process of clinical practice, clinical pharmacists should fully disclose the benefits and risks of drugs to the doctors and patients, and provide good drug information for clinicians, so as to ensure patients' medication to be safe, effective and reasonable.

Key words: clinical pharmacist, anemia, recombinant human erythropoietin

中图分类号:

R969.3

周殿友, 习加喜, 龚倩. 1例晚期非小细胞肺癌并发重度贫血的药学监护[J]. 中国药物警戒, 2016, 13(12): 757-760.

ZHOU Dian-you, XI Jia-xi, GONG Qian. Pharmaceutical Care for One Advanced Non-small Cell Lung Cancer Complicated with Severe Anemia[J]. Chinese Journal of Pharmacovigilance, 2016, 13(12): 757-760.

参考文献

[1] Depierre A, Lagrange J L, Theobald S, et al. Standards, options and recommendations for the management of non small cell lung carcinoma[J]. Bull Cancer 2003, 90(2):151-166.
[2] Groopman J E, Itri L M. Chemotherapy-induced anemia in adults: incidence and treatment[J]. J Natl Cancer Inst, 1999, 91(19):1616-1634.
[3] Glaspy J,Degos L,Dicato M,et al. Comparable efficacy of epoetinalfa for anemic cancer patients receiving platinum and nonplatinum-based chemotherapy:a retrospective subanalysis of two large, community-based trials[J]. The Oncologist, 2002, 7(2):126-135.
[4] 王静, 李峻岭, 石远凯. 吉西他滨联合顺铂在非小细胞肺癌辅助化疗中的应用[J].中国全科医学, 2012, 15 (3C): 987-989.
[5] 王伟兰, 陈超, 郭代红. 吉西他滨相关性贫血的主动监测研究[J].中国药物应用与监测, 2014, 1(1): 29-31.
[6] Wood P A, Hrushkesky W J M. Cisplatin -associated anemia: an erythropoietin deficiency syndrome[J]. J Clin Invest , 1995, 95( 4):1650-1659.
[7] 中华人民共和国卫生部. 临床输血计数指南——内科输血指南[J]. 中国临床医师, 2001, 29(3): 29-30.
[8] CSCO肿瘤相关性贫血专家委员会. 肿瘤相关性贫血临床实践指南（2012-2013版）[EB/OL]. (2012-09)[2015-06-01].http://d.dxy.cn/detail/5913390.
[9] NCCN. NCCN Clinical practice guidelines in oncology. Cancer and chemotherapy induced anemia(2015.v1)[EB/OL]. (2014-06-26)[2015-06-25].http://www.nccn.org.
[10] 张艳华. 肿瘤相关性贫血治疗现状与药学监护[C]// 临床药学高端论坛之二十三肿瘤相关性贫血的治疗现状与药学监护讲义. 2012.
[11] Crawford J, Demetri G D, Gabrilove J L, et al. Clinical benefits of epoetinalfa therapy in patients with lung cancer[J]. Clin Lung Cancer, 2002, 3(3):180-190.
[12] Bohlius J, Langensiepen S, Schwarzer G, et al. Recombinant human erythropoietin and overall survival in cancer patients: result of a comprehensive meta-analysis[J]. JNCI J Natl cancer Inst, 2005,97(7): 489-498.
[13] Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: A meta-analysis of randomised trials[J]. The Lancet, 2009,373(9674):1532-1542.
[14] Wright J R, Ung Y C, Julian J A, et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia[J]. J ClinOncol, 2007, 25(9):1027-1032.
[15] Smith R E, Aapro M S, Ludwig H, et al. Darbepoetin Alfa for the Treatment of Anemia in Patients With Active Cancer Not Receiving Chemotherapy or Radiotherapy: Results of a Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study[J]. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology, 2008, 26(7):1040-1050.
[16] Untch M, Fasching P A, Bauerfeind I, et al. PREPARE trial. A randomized phase III trial comparing preoperative, dose-dense, doseintensified chemotherapy with epirubicin, paclitaxel and CMF with a standard dosed epirubicin/cyclophosphamide followed by paclitaxel {+/-} darbepoetinalfa in primary breast cancer: A preplanned interim analysis of efficacy at surgery [J]. J ClinOncol, 2008,26(Suppl15):Abstract 517.
[17] EMA. EPAR summary for the public, Abseamed epoetin alfa[EB/OL]. (2012-02-07)[2015-06-26].http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000727/WC500020663.pdf.
[18] FDA. Highlights prescribing information. Epogen (epoetin alfa). [EB/OL]. (2013-12)[2015-06-26]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/103234s5323lbl.pdf.
[19] NCCN.NCCN clinical practice guidelines in oncology. Non-small cell lung cancer (Version 1. 2015)[EB/OL]. (2014-10-26)[2015-06-01]. http://www.nccn.org/patient.

1例晚期非小细胞肺癌并发重度贫血的药学监护

Pharmaceutical Care for One Advanced Non-small Cell Lung Cancer Complicated with Severe Anemia

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	范凯凯, 王聪, 刘洪峰, 王西勇. 临床药师对某院丙氨酰谷氨酰胺注射液应用干预分析[J]. 中国药物警戒, 2024, 21(2): 181-184.
[2]	陈婕, 秦侃. 肠外营养个体化给药实践评价[J]. 中国药物警戒, 2023, 20(7): 812-816.
[3]	刘婧, 夏亮, 张世杰. 1例多元药物过敏急性胰腺炎患者行药物激发试验的药学监护[J]. 中国药物警戒, 2023, 20(7): 822-824.
[4]	苏甦, 伍诗琪, 张青霞, 闫素英. 1例吲达帕胺致粒细胞缺乏症患者的药学监护[J]. 中国药物警戒, 2023, 20(11): 1282-1285.
[5]	卫红涛, 沈素, 李丹丹, 廖音. 705例神经内科问题医嘱的帕累托图分析[J]. 中国药物警戒, 2022, 19(8): 900-903.
[6]	原小陇, 万齐华, 陶东红, 祁浩, 王爱霞. 1例甲氨蝶呤片严重中毒患者的药学监护[J]. 中国药物警戒, 2022, 19(8): 924-928.
[7]	孙雪林, 张攀, 胡欣. 1例维得利珠单抗治疗重症溃疡性结肠炎的药学监护[J]. 中国药物警戒, 2022, 19(7): 782-785.
[8]	唐静雅. 临床药师参与1例肠外营养相关性肝损伤治疗的药学监护[J]. 中国药物警戒, 2022, 19(7): 786-788.
[9]	杨宝春, 孙欣, 杨欣, 吴琳, 王丽萍. 临床药师参与1例尿路感染伴药物热患者药学实践[J]. 中国药物警戒, 2022, 19(5): 572-573.
[10]	陈方方, 张红旭. 大剂量甲氨蝶呤治疗原发性中枢神经系统淋巴瘤的药学实践[J]. 中国药物警戒, 2022, 19(4): 446-449.
[11]	李友佳, 谢姣, 姚红伊, 计成. 1例甲状旁腺功能减退性心肌病患者的药学监护[J]. 中国药物警戒, 2022, 19(11): 1254-1257.
[12]	蔡乐乐, 张卓琳, 李歆, 方丹君, 韩峰. 国内外缺铁性贫血药物治疗的安全性和有效性研究进展[J]. 中国药物警戒, 2022, 19(11): 1262-1265.
[13]	庄红艳, 刘珊珊, 果伟, 薛春苗, 何悦, 赵燕. 1例糖尿病足合并多种并发症患者的中西药学监护[J]. 中国药物警戒, 2022, 19(1): 103-106.
[14]	吴红, 李歆, 韩峰. 某三级肿瘤专科医院单克隆抗体类新型抗肿瘤药临床使用合理性与安全性分析[J]. 中国药物警戒, 2021, 18(10): 960-964.
[15]	曲国红, 陈喆. 1例直肠癌患者新辅助化疗发生肺栓塞的药学干预实践[J]. 中国药物警戒, 2021, 18(1): 80-83.